Tag: clinical phase 3 trial
Palforzia Shows Positive Results in Peanut-Allergic Children Ages 1-3 in Phase...
73.5% of patients treated with PALFORZIA tolerated a 600 mg single dose of peanut protein at 12 months.
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler...
81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Biologic Showing Promise as Food Allergy Treatment in Ongoing Phase 3...
Assessment for both single agent and add-on therapy.
Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...
73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.
Private Law Firm to Investigate Claims on Behalf of Investors in...
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Another delay for the long-awaited therapy.
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
Infants and young children finally get relief from eczema’s terrible itch
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
Majority of patients achieved histological disease remission in 16 weeks.
